Aileron Therapeutics, Inc. (ALRN) stock declined over -13.39% intraday to trade at $0.26 a share on NASDAQ. The stock opened with a loss of -31.58% at $0.305 and touched an intraday high of $0.305, falling -13.33% against the last close of $0.3. The stock went to a low of $0.252 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Aileron Therapeutics, Inc. (NASDAQ: ALRN) stock price is $0.26 as of the last check on Thursday, June 30. During the trading session, ALRN stock reached the peak price of $0.305 while $0.252 was the lowest point it dropped to.
The NASDAQ listed ALRN is part of Biotechnology industry that operates in the broader Health Care sector. Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.
Dr. Manuel C. Aivado
Pres, CEO & Director
Mr. Richard J. Wanstall M.B.A.
SVP, CFO & Treasurer
Dr. Vojislav Vukovic M.D., Ph.D.
Sr. VP & Chief Medical Officer
Dr. D. Allen Annis Ph.D.
Sr. VP of Research
ALRN stock traded closed the last session at $0.26, which is $-0.04 or -13.39% lower than its previous close of $0.3. ALRN's current trading price is -1.25% lower than its 52-week high of $1.34 where as its distance from 52-week low of 0.26% is -80.60%.
Number of ALRN employees currently stands at -. ALRN operates from 285 Summer Street, Suite 101, Boston, MA 02210, United States.
Official Webiste of $ALRN is: https://www.aileronrx.com
ALRN stock volume for the day was 1,059,776 shares while in the previous session number of ALRN shares traded was 1,053,796 . The average number of ALRN shares traded daily for last 3 months was 335.84 Thousands.
The percentage change in ALRN stock occurred in the recent session was -13.39% while the dollar amount for the price change in ALRN stock was $-0.04.
In the recent session, the day high for ALRN stock was $0.305 while the low for ALRN stock touched on the day was $0.252.
The market value of ALRN currently stands at 24.89 Million with its latest stock price at $0.26 and 90.67 Million of its shares outstanding.